David Anderson
Research Subjects
David Anderson has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Matthew Rizzo
Department of Neurological Sciences, College of Medicine, University of Nebraska Medical Center (UNMC), USA; Fred & Pamela Buffett Cancer Center, UNMC, USA
3 shared publications- Allen Best
Clinical Ink, Winston-Salem, NC 27101, USA
2 shared publications - Anna Keil
Clinical Ink, Winston-Salem, NC 27101, USA
2 shared publications - Brian Severson
Clinical Ink, Winston-Salem, NC 27101, USA
2 shared publications - Dan Amato
Clinical Ink, Winston-Salem, NC 27101, USA
2 shared publications - Earl Ray Dorsey
Center for Health + Technology, University of Rochester, Rochester, NY, USA
2 shared publications
Latest Publications
- Open Access
- 18 October 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in TechRxiv
Technical Validation of a Novel GCP-Compliant Platform for Real-Time CGM Capture in FDA-Regulated Clinical Trials
FDA guidance recommends continuous glucose monitoring (CGM) for diabetes clinical trials. Real-time monitoring in such trials demands high-speed data frameworks. Here, we sought to develop a fully GCP-compliant platform that integrates with CGM devices and rapidly transmits regulatory submission quality data to study servers. Software acquired glucose readings directly from Dexcom G6 CGM transmitters and sensors via Bluetooth. Live transmitter samples were considered real-time readings; backfill samples were excluded from real-time classification. Software synchronized with study servers after each sample acquisition, pending network connectivity. Descriptive statistics were evaluated for this pilot study. CGM readings (n=16,032) were generated three separate study periods. Median inter-sample interval was 5.0 minutes, and 99.4% of all sample intervals collected within the manufacturer recommended collection period were between 4.9 and 5.1 minutes. Sample validity was high (98.8%), where 1.3% of samples were lost to sensor warmup and 0.05% of samples were lost to sensor error. Real-time measurements made up 96.9% of readings. Median transmitter sync time was 9 to 14 seconds across study periods. Server upload times were fastest at 1 second; approximately 85% of all samples were uploaded within 10 minutes. Participant showed normal glycemic variability (19.7%) and time-in-range (97.3%). We developed a fully GCP-compliant high-speed data platform directly integrated with CGM devices. There is potential for low latency data availability – on the order of seconds – and further investigation is required to understand sources of server upload lag, for example network connectivity. Future development of this platform will include integrated hypo forms triggered by CGM data streams. Further work is needed to understand network dynamics of this framework in a larger study cohort.
- 18 October 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in TechRxiv
Open AccessTechnical Validation of a Novel GCP-Compliant Platform for Real-Time CGM Capture in FDA-Regulated Clinical Trials
FDA guidance recommends continuous glucose monitoring (CGM) for diabetes clinical trials. Real-time monitoring in such trials demands high-speed data frameworks. Here, we sought to develop a fully GCP-compliant platform that integrates with CGM devices and rapidly transmits regulatory submission quality data to study servers. Software acquired glucose readings directly from Dexcom G6 CGM transmitters and sensors via Bluetooth. Live transmitter samples were considered real-time readings; backfill samples were excluded from real-time classification. Software synchronized with study servers after each sample acquisition, pending network connectivity. Descriptive statistics were evaluated for this pilot study. CGM readings (n=16,032) were generated three separate study periods. Median inter-sample interval was 5.0 minutes, and 99.4% of all sample intervals collected within the manufacturer recommended collection period were between 4.9 and 5.1 minutes. Sample validity was high (98.8%), where 1.3% of samples were lost to sensor warmup and 0.05% of samples were lost to sensor error. Real-time measurements made up 96.9% of readings. Median transmitter sync time was 9 to 14 seconds across study periods. Server upload times were fastest at 1 second; approximately 85% of all samples were uploaded within 10 minutes. Participant showed normal glycemic variability (19.7%) and time-in-range (97.3%). We developed a fully GCP-compliant high-speed data platform directly integrated with CGM devices. There is potential for low latency data availability – on the order of seconds – and further investigation is required to understand sources of server upload lag, for example network connectivity. Future development of this platform will include integrated hypo forms triggered by CGM data streams. Further work is needed to understand network dynamics of this framework in a larger study cohort.
- Open Access
Wearable Sensor-Based Assessments for Remotely Screening Early-Stage Parkinson’s Disease
Prevalence estimates of Parkinson’s disease (PD)—the fastest-growing neurodegenerative disease—are generally underestimated due to issues surrounding diagnostic accuracy, symptomatic undiagnosed cases, suboptimal prodromal monitoring, and limited screening access. Remotely monitored wearable devices and sensors provide precise, objective, and frequent measures of motor and non-motor symptoms. Here, we used consumer-grade wearable device and sensor data from the WATCH-PD study to develop a PD screening tool aimed at eliminating the gap between patient symptoms and diagnosis. Early-stage PD patients (n = 82) and age-matched comparison participants (n = 50) completed a multidomain assessment battery during a one-year longitudinal multicenter study. Using disease- and behavior-relevant feature engineering and multivariate machine learning modeling of early-stage PD status, we developed a highly accurate (92.3%), sensitive (90.0%), and specific (100%) random forest classification model (AUC = 0.92) that performed well across environmental and platform contexts. These findings provide robust support for further exploration of consumer-grade wearable devices and sensors for global population-wide PD screening and surveillance.
Open AccessWearable Sensor-Based Assessments for Remotely Screening Early-Stage Parkinson’s Disease
Prevalence estimates of Parkinson’s disease (PD)—the fastest-growing neurodegenerative disease—are generally underestimated due to issues surrounding diagnostic accuracy, symptomatic undiagnosed cases, suboptimal prodromal monitoring, and limited screening access. Remotely monitored wearable devices and sensors provide precise, objective, and frequent measures of motor and non-motor symptoms. Here, we used consumer-grade wearable device and sensor data from the WATCH-PD study to develop a PD screening tool aimed at eliminating the gap between patient symptoms and diagnosis. Early-stage PD patients (n = 82) and age-matched comparison participants (n = 50) completed a multidomain assessment battery during a one-year longitudinal multicenter study. Using disease- and behavior-relevant feature engineering and multivariate machine learning modeling of early-stage PD status, we developed a highly accurate (92.3%), sensitive (90.0%), and specific (100%) random forest classification model (AUC = 0.92) that performed well across environmental and platform contexts. These findings provide robust support for further exploration of consumer-grade wearable devices and sensors for global population-wide PD screening and surveillance.
- Open Access
- 16 August 2024
- Published by MDPI AG in Preprints.org
Wearable Sensor-Based Assessments for Remotely Screening Early-Stage Parkinson’s Disease
Prevalence estimates of Parkinson’s disease (PD) – the fastest growing neurodegenerative disease – are underestimated due to issues surrounding diagnostic accuracy, symptomatic undiagnosed cases, suboptimal prodromal monitoring, and limited screening access. Remotely monitored wearable devices and sensors provide precise, objective, and frequent measures of motor and non-motor symptoms. Here, we used consumer-grade wearable device and sensor data from the WATCH-PD study to develop a PD screening tool aimed at eliminating gaps between patient symptoms and diagnosis. Early-stage PD (n=82) and age-matched comparison (n=50) participants completed a multidomain assessment battery during a one-year longitudinal multicenter study. Using disease- and behavior-relevant feature engineering and multivariate machine learning modeling of early-stage PD status, we developed a highly accurate (92.3%), sensitive (90.0%), and specific (100%) Random Forest classification model (AUC=0.92) that performed well across environmental contexts. These findings provide robust support for further exploring consumer-grade wearable devices and sensors for global population-wide PD screening and surveillance.
- 16 August 2024
- Published by MDPI AG in Preprints.org
Open AccessWearable Sensor-Based Assessments for Remotely Screening Early-Stage Parkinson’s Disease
Prevalence estimates of Parkinson’s disease (PD) – the fastest growing neurodegenerative disease – are underestimated due to issues surrounding diagnostic accuracy, symptomatic undiagnosed cases, suboptimal prodromal monitoring, and limited screening access. Remotely monitored wearable devices and sensors provide precise, objective, and frequent measures of motor and non-motor symptoms. Here, we used consumer-grade wearable device and sensor data from the WATCH-PD study to develop a PD screening tool aimed at eliminating gaps between patient symptoms and diagnosis. Early-stage PD (n=82) and age-matched comparison (n=50) participants completed a multidomain assessment battery during a one-year longitudinal multicenter study. Using disease- and behavior-relevant feature engineering and multivariate machine learning modeling of early-stage PD status, we developed a highly accurate (92.3%), sensitive (90.0%), and specific (100%) Random Forest classification model (AUC=0.92) that performed well across environmental contexts. These findings provide robust support for further exploring consumer-grade wearable devices and sensors for global population-wide PD screening and surveillance.
- Open Access
- 1 July 2020
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 2 (2) , fcaa140
Global brain network dynamics predict therapeutic responsiveness to cannabidiol treatment for refractory epilepsy
Refractory epilepsy is a chronic brain network disorder characterized by unresponsiveness to multiple (>2) anti-epileptic drugs. Cannabidiol, a non-psychotropic neuroactive substance, is an emerging anti-epileptic treatment that was recently approved by the US Food and Drug Administration for the treatment of refractory epilepsy, especially Lennox Gastaut syndrome and Dravet syndrome. Here, we evaluated associations between global brain network dynamics and related changes and responsiveness to cannabidiol therapy using a combination of electroencephalography phase coherence and graph theoretical analyses. Refractory epilepsy patients with Lennox Gastaut syndrome or Dravet syndrome underwent serial electroencephalography testing prior to and during cannabidiol treatment. Patients showing greater than 70% seizure frequency reduction were classified as treatment responders for the purposes of this study. We calculated inter-electrode electroencephalography phase coherence in delta (1–3 Hz), theta (4–7 Hz), alpha (8–12 Hz) and beta (13–30 Hz) frequency bands. Graph theoretical analysis of brain network dynamics was extracted from phase coherence to evaluate measures of network integration (i.e. characteristic path length, global efficiency and degree) and segregation (i.e. modularity and transitivity). We found that responders, relative to non-responders, showed increased network integration—as indexed by relatively higher global efficiency and lower degree—and increased network segregation—as indexed by relatively higher modularity—exclusively in the beta-frequency band. We also found that larger cannabidiol dosages were associated with increased network integration—as indexed by higher global efficiency with increasing dose—and increased network segregation—as indexed by lower transitivity with increasing dose—in the delta, theta and alpha frequency bands. In summary, we demonstrate novel effects of cannabidiol on brain network dynamics with important implications for the treatment of refractory epilepsy and, possibly, across broader research applications in the future.
- 1 July 2020
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 2 (2) , fcaa140
Open AccessGlobal brain network dynamics predict therapeutic responsiveness to cannabidiol treatment for refractory epilepsy
Refractory epilepsy is a chronic brain network disorder characterized by unresponsiveness to multiple (>2) anti-epileptic drugs. Cannabidiol, a non-psychotropic neuroactive substance, is an emerging anti-epileptic treatment that was recently approved by the US Food and Drug Administration for the treatment of refractory epilepsy, especially Lennox Gastaut syndrome and Dravet syndrome. Here, we evaluated associations between global brain network dynamics and related changes and responsiveness to cannabidiol therapy using a combination of electroencephalography phase coherence and graph theoretical analyses. Refractory epilepsy patients with Lennox Gastaut syndrome or Dravet syndrome underwent serial electroencephalography testing prior to and during cannabidiol treatment. Patients showing greater than 70% seizure frequency reduction were classified as treatment responders for the purposes of this study. We calculated inter-electrode electroencephalography phase coherence in delta (1–3 Hz), theta (4–7 Hz), alpha (8–12 Hz) and beta (13–30 Hz) frequency bands. Graph theoretical analysis of brain network dynamics was extracted from phase coherence to evaluate measures of network integration (i.e. characteristic path length, global efficiency and degree) and segregation (i.e. modularity and transitivity). We found that responders, relative to non-responders, showed increased network integration—as indexed by relatively higher global efficiency and lower degree—and increased network segregation—as indexed by relatively higher modularity—exclusively in the beta-frequency band. We also found that larger cannabidiol dosages were associated with increased network integration—as indexed by higher global efficiency with increasing dose—and increased network segregation—as indexed by lower transitivity with increasing dose—in the delta, theta and alpha frequency bands. In summary, we demonstrate novel effects of cannabidiol on brain network dynamics with important implications for the treatment of refractory epilepsy and, possibly, across broader research applications in the future.
- 1 August 2019
- Published by Elsevier in Clinical Neurophysiology
- Vol. 130 (8) , 1243-1252
Neurophysiological evidence of impaired attention and working memory in untreated hematologic cancer patients
- 1 August 2019
- Published by Elsevier in Clinical Neurophysiology
- Vol. 130 (8) , 1243-1252
Neurophysiological evidence of impaired attention and working memory in untreated hematologic cancer patients
- Open Access
- 25 June 2019
- Published by The University of Iowa
- Vol. 10
Spatially Biased Eye Movements in Older Drivers with Glaucoma and Visual Field Defects
Patients with glaucoma are at greater driving safety risk due to visual field defects. These driving safety risks may be mitigated by compensatory eye movements. We measured spatial allocation of eye movements in a panoramic driving simulator in 8 drivers with glaucoma and 5 with suspected glaucoma. All completed a driving simulator visual field task under three separate conditions: (1) parked with a naturalistic background (Baseline condition); (2) driving on a rural highway (Driving condition); and (3) driving and completing a competing auditory attention task (PASAT condition). Results showed that: (1) drivers with larger binocular visual field defects showed more restricted, spatially biased eye movements, and (2) greater task load led to more spatially biased eye movements in drivers with larger binocular visual field defects. Findings provide preliminary evidence of eye movement patterns that may reflect compensatory behaviors in drivers with glaucomatous visual fields. Better understanding of the relationship between visual field deficits, eye movement patterns, and driving in glaucoma can help inform countermeasures to improve safety and mobility in drivers with visual impairments.
- 25 June 2019
- Published by The University of Iowa
- Vol. 10
Open AccessSpatially Biased Eye Movements in Older Drivers with Glaucoma and Visual Field Defects
Patients with glaucoma are at greater driving safety risk due to visual field defects. These driving safety risks may be mitigated by compensatory eye movements. We measured spatial allocation of eye movements in a panoramic driving simulator in 8 drivers with glaucoma and 5 with suspected glaucoma. All completed a driving simulator visual field task under three separate conditions: (1) parked with a naturalistic background (Baseline condition); (2) driving on a rural highway (Driving condition); and (3) driving and completing a competing auditory attention task (PASAT condition). Results showed that: (1) drivers with larger binocular visual field defects showed more restricted, spatially biased eye movements, and (2) greater task load led to more spatially biased eye movements in drivers with larger binocular visual field defects. Findings provide preliminary evidence of eye movement patterns that may reflect compensatory behaviors in drivers with glaucomatous visual fields. Better understanding of the relationship between visual field deficits, eye movement patterns, and driving in glaucoma can help inform countermeasures to improve safety and mobility in drivers with visual impairments.
- 20 August 2018
- Published by SAGE Publications in Transportation Research Record: Journal of the Transportation Research Board
- Vol. 2672 (37) , 64-73
Electrophysiological Measure of Impaired Information Processing in Drivers with Hematological Malignancy
The broad goal of this study is to measure remote effects of cancer on brain physiology and behaviors that underpin instrumental activities of daily living such as automobile driving. Studies of hematological malignancies (HM) have demonstrated impairments in multiple brain functions shown to be critical for safe automobile driving. In the current pilot study, brain physiology during driving simulation was examined in 14 HM patients and 13 healthy comparison drivers. Electroencephalography was used to measure the eye fixation-related potential (EFRP)—a positive amplitude deflection evoked approximately 100 milliseconds after eye movement termination. Previous studies have demonstrated sensitivity of EFRP activity to information-processing capacity. All drivers completed visual search tasks to evaluate the relationship between driving-related changes in performance and EFRP activity. Results showed smaller EFRP amplitudes in drivers who had: (1) greater driving-related changes in visual search performance (p = 0.03, Cohen’s d = 0.91); and (2) HM diagnosis (p = 0.18, Cohen’s d = 0.54). Extending previous studies, these results provide neural evidence of reduced information-processing capacity associated with cancer diagnosis. Future large-scale studies are needed to confirm these results, given the high level of uncertainty and small sample size. This study provides a novel platform for linking changes in brain physiology and safety-critical driving behaviors.
- 20 August 2018
- Published by SAGE Publications in Transportation Research Record: Journal of the Transportation Research Board
- Vol. 2672 (37) , 64-73
Electrophysiological Measure of Impaired Information Processing in Drivers with Hematological Malignancy
The broad goal of this study is to measure remote effects of cancer on brain physiology and behaviors that underpin instrumental activities of daily living such as automobile driving. Studies of hematological malignancies (HM) have demonstrated impairments in multiple brain functions shown to be critical for safe automobile driving. In the current pilot study, brain physiology during driving simulation was examined in 14 HM patients and 13 healthy comparison drivers. Electroencephalography was used to measure the eye fixation-related potential (EFRP)—a positive amplitude deflection evoked approximately 100 milliseconds after eye movement termination. Previous studies have demonstrated sensitivity of EFRP activity to information-processing capacity. All drivers completed visual search tasks to evaluate the relationship between driving-related changes in performance and EFRP activity. Results showed smaller EFRP amplitudes in drivers who had: (1) greater driving-related changes in visual search performance (p = 0.03, Cohen’s d = 0.91); and (2) HM diagnosis (p = 0.18, Cohen’s d = 0.54). Extending previous studies, these results provide neural evidence of reduced information-processing capacity associated with cancer diagnosis. Future large-scale studies are needed to confirm these results, given the high level of uncertainty and small sample size. This study provides a novel platform for linking changes in brain physiology and safety-critical driving behaviors.